Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Sodium Butyrate
Therapeutic Area : Undisclosed
Study Phase : Undisclosed
Sponsor : Compound Solutions
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 17, 2024
Lead Product(s) : Sodium Butyrate
Therapeutic Area : Undisclosed
Highest Development Status : Undisclosed
Sponsor : Compound Solutions
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Sodium Butyrate
Therapeutic Area : Immunology
Study Phase : Undisclosed
Sponsor : Arthritis Foundation
Deal Size : Inapplicable
Deal Type : Inapplicable
Effects of Administration of SCFA in Rheumatoid Arthritis Inadequate Responders
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 08, 2023
Lead Product(s) : Sodium Butyrate
Therapeutic Area : Immunology
Highest Development Status : Undisclosed
Sponsor : Arthritis Foundation
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Sodium Butyrate
Therapeutic Area : Gastroenterology
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : An oral, targeted metabolite delivery platform enables butyrate to achieve its maximum therapeutic potential with an initial focus on helping patients who struggle with gastrointestinal issues like mild to moderate ulcerative colitis and food allergies.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 24, 2023
Lead Product(s) : Sodium Butyrate
Therapeutic Area : Gastroenterology
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Sodium Butyrate
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase II/ Phase III
Sponsor : Stanley Medical Research Institute
Deal Size : Inapplicable
Deal Type : Inapplicable
Sodium Butyrate For Improving Cognitive Function In Schizophrenia
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 05, 2017
Lead Product(s) : Sodium Butyrate
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase II/ Phase III
Sponsor : Stanley Medical Research Institute
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Sodium Butyrate
Therapeutic Area : Nutrition and Weight Loss
Study Phase : Undisclosed
Sponsor : Global Alliance for Improved Nutrition | DSM Ltd | Unilever
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
May 03, 2013
Lead Product(s) : Sodium Butyrate
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Undisclosed
Sponsor : Global Alliance for Improved Nutrition | DSM Ltd | Unilever
Deal Size : Inapplicable
Deal Type : Inapplicable